他汀类药物在慢性阻塞性肺疾病稳定期患者中的作用

发布时间：2018-03-14 04:22

本文选题：肺疾病　切入点：慢性阻塞性　出处：《实用医学杂志》2015年11期 　论文类型：期刊论文

【摘要】：目的:探讨他汀类药物在慢性阻塞性肺疾病稳定期患者治疗中的作用。方法:83例慢性阻塞性肺疾病稳定期患者随机分为治疗组(41例)和对照组(42例),对照组按诊疗常规予以治疗,治疗组在常规治疗基础上加用瑞舒伐他汀钙片20 mg/d,观察两组治疗前、治疗后12、24、48周时血清CRP水平、肺功能[第1秒钟用力呼气容积(FEV1)、FEV1占预计值百分比(FVC%pred)及COPD评估测试问卷(CAT)变化。结果:在12周时,两组患者血清CRP水平、FEV1、FVC%pred及CAT评分较治疗前有所改善;两组间比较,血清CRP水平及CAT评分差异有统计学意义(P0.05),FEV1、FVC%pred差异无统计学意义(P0.05)。24、48周时,两组血清CRP水平、FEV1、FVC%pred及CAT评分较治疗前都有所改善,两组间比较差异均有统计学意义(P0.05)。结论:他汀类药物可以减轻COPD患者炎症反应,改善肺功能及提高生活质量。
[Abstract]:Objective: to investigate the role of statins in the treatment of stable patients with chronic obstructive pulmonary disease (COPD). Methods: 83 cases of stable COPD patients were randomly divided into treatment group (n = 41) and control group (n = 42). To be treated by routine therapy, In the treatment group, 20 mg / d of recuvastatin calcium tablets were added to the routine therapy. The serum CRP levels were observed before and after treatment for 12 ~ 24 weeks. Pulmonary function [FEV1 / FEV1 as a percentage of predicted value] and COPD evaluation questionnaire (CAT-1). Results: at 12 weeks, serum CRP levels, FEV1FVCpred and CAT scores were improved in both groups compared with those before treatment. There was significant difference in serum CRP level and CAT score. There was no significant difference in serum CRP level and FEV1FVCpred and CAT score between the two groups at 48 weeks after treatment. Conclusion: statins can reduce inflammation, improve lung function and improve quality of life in patients with COPD.
【作者单位】：广东省佛山市禅城区中心医院呼吸内科;
【分类号】：R563.9

【参考文献】